{"entity":{"id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","aka":[],"tldr":"A phase 2 trial of Zilovertamab vedotin, Cyclophosphamide, Doxorubicin, Rituximab and Prednisone in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) is a phase 2 interventional study registered as NCT05406401 by Merck Sharp & Dohme LLC, with 60 participants enrolled, started 2022-07-14 and due to reach its primary completion in 2029-04-26. Interventions recorded: Zilovertamab Vedotin, Cyclophosphamide, Doxorubicin, Rituximab, Rituximab Biosimilar and Prednisone.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05406401","url":"https://clinicaltrials.gov/study/NCT05406401"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["zilovertamab-vedotin","cyclophosphamide","doxorubicin","rituximab","prednisone"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05406401","phase":"2","setting":"A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)","sponsor":"Merck Sharp & Dohme LLC","enrolled":60,"outcomes":[]},"route":"/trials/nct05406401/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}